Drugs / VRDN-003
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07155668 | Jul 2025 → May 2026 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06812325 | Feb 2025 → Apr 2026 overdue | endocrine exophthalmos | Viridian Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06625398 | Aug 2024 → Mar 2026 overdue | endocrine exophthalmos | Viridian Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06625411 | Aug 2024 → Feb 2026 overdue | endocrine exophthalmos | Viridian Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRDN-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155668 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT06625398 ↗ |
| Route | Subcutaneous | “subcutaneously administered” NCT06625398 ↗ |
| Target | IGF1R | “directed against the Insulin-like Growth Factor-1 receptor (IGF-1R)” NCT07155668 ↗ |